|Print View Attached Docs:|
|Methodology:||Enzyme-Linked Immunosorbent Assay (ELISA)|
|Performed:||Monday, Wednesday, Friday|
|Released:||1-5 days after setup at PeaceHealth Laboratories’ reference lab.|
|Specimen Collection Details|
|Collection:||Random stool in a sterile plastic container. Do not add preservatives.|
|Stability:||5 days ambient, 5 days refrigerated, or 1 year frozen.|
|Standard Volume:||2- gm stool.|
|Minimum Volume:||10 gm stool.|
|Comments:||Calprotectin is a valuable clinical marker for inflammation associated with infectious, ulcerative and malignant processes of the GI tract. It is the non-invasive “test of choice” for differentiating Irritable Bowel (IBS) from Inflammatory Bowel Disease (IBD).
Fecal Calprotectin is an indicator of the presence of neutrophils in stool and is not specific for IBD. Other intestinal ailments including GI infections and colorectal cancer can result in elevated concentrations of calprotectin. The diagnosis of IBD cannot be established solely on the basis of a positive calprotectin result. Patients with IBD fluctuate between active and inactive stages of disease. Calprotectin results may also fluctuate. GI bleeding of as much as 100 mL per day will increase the fecal calprotectin concentration by only 15 µg/g.
|≤ 50 µg/g||
Borderline elevated; test should be re-evaluated in 4-6 weeks.
|≥ 121 µg/g||
Abnormal; suggestive of inflammatory bowl disease (IBD).